The role of recombinant human erythropoietin in the treatment of thalassemia

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 129-138

  Rachmilewitz, Eliezer A ^a   Aker, Memet ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLOBIN; HEMOGLOBIN F; HYDROXYUREA; IRON; RECOMBINANT ERYTHROPOIETIN;

BETA THALASSEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG POTENTIATION; ERYTHROPOIESIS; GLOBIN SYNTHESIS; HUMAN; META ANALYSIS; METHODOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SPLENECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION;

PAPIO;

EID: 0031876330     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10470.x     Document Type: Conference Paper

References (45)

1. SPIVAK, J. L. 1986; The mechanisms of action of erythropoietin. Int. J. Cell Cloning. 4: 139-143.
2. LIN, F. K., S. SUGGS, et al. 1985. Cloning and expression of human erythropoietin gene. Proc. Natl. Acad. Sci. USA. 82: 7580-7584.
3. AL-KHATTI, A., R. VEITH, et al. 1987. Stimulation of Hb F synthesis by erythropoietin in baboons. New Eng. J. Med. 317: 415-420.
4. LEROY-VIARD, K., P. ROUGER-FESSARD, et al. 1991. Improvement of mouse beta-thalassemia. Blood 78: 1596-1602.
5. FIBACH, E., A. N. SCHECHTER, et al. 1994. Reducing erythropoietin in cultures of human erythroid precusors elevates the proportion of fetal hemoglobin. Br. J. Haematol. 88: 39-45.
6. RODGERS, G. P., G. J. DOVER, et al. 1993. Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. New Eng. J. Med. 328: 71-80.
7. OLIVIERI, N. F. 1996. Reactivation of fetal hemoglobin in patients with thalassemia. Semin. Hematol. 33: 24-42.
8. HAMMOND, G. D., A. ISHIKAWA, et al. 1962. Relationship between erythropoiesis and severity of anemia in hypoplastic and hemolytic states. In Erythropoiesis: 351. Grune and Stratton. Philadelphia, PA.
9. MANOR, D., E. FIBACH, et al. 1986. Erythropoietin activity in the serum of thalassemia patients. Scand. J. Haematol. 37: 221-228.
10. BUEMI, M., A. SARDO, et al. 1987. Pattern of plasma erythropoietin in Cooley's Disease. In Thalassemia Today. G. Sirchia & A. Zanella, Eds.: 627-631. Centro Transfusionale, Milan.
11. NISLI, G., K. KAVAKLI, et al. 1997. Serum erythropoietin levels in patients with B thalassemia major and intermedia. Pediatr. Hematol. Oncol. 14: 161-167.
12. SHERWOOD, J. B., E. GOLDWASSER, et al. 1986. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 67: 46-49.
13. ALESSI, M., G. LONGO, et al. 1990. Erythropoietin serum levels in thalassemia. Ann. N.Y. Acad. Sci. 612: 534-535.
14. DORE, F., S. BONGIGLI, et al. 1993. Serum erythropoietin levels in thalassemia intermedia. Ann. Hematol. 67: 183-186.
15. ANDRE, M., P. BERGMAN, et al. 1991. Serum immunoreactive erythropoietin level: a new parameter for monitoring transfusion management in thalassemia. Nouv. Rev. Fr. Hematol. 33: 299-302.
16. ESCHBACH, J. W. 1989. The anemia of chronic renal failure: Pathophysiology and the effect of recombinant erythropoietin. Kidney Int. 35: 134-148.
17. GOLDBERG, M. A., C. BRUGNARA, et al. 1990. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N. Eng. J. Med. 323: 366-372.
18. CHENG, I. K. P. & M. B. LU, et al. 1993. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am. J. Nephrol. 13: 142-148.
19. WINEARLS, C. G. & R. T. HUGHES, et al. 1992. Erythropoietin dose requirement in a patient with Hb H disease and renal failure. Nephrol. Dial. Transplant. 7: 1052-1054.
20. COZMA, G. & M. C. COZMA, et al. 1992. Beneficial effect of recombinant human erythropoietin in thalassemic patients on dialysis. Nephrol. Dial. Transplant. 7: 82-83.
21. LAI, K. N., K. C. WONG, et al. 1992. Use of recombinant erythropoietin in thalassemic patients on dialysis. Am. J. Kid. Dis. 19: 239-245.
22. KAGAN, A., L. SINAY-TREIMAN, et al. 1992. Recombinant human erythropoietin for anemia of end-stage renal failure in thalassemia trait. Nephron 62: 229-230.
23. BELLIZZI, V., L. DE NICOLA, et al. 1997. Fetal proteins and chronic treatment with low dose erythropoietin. J. Lab. Clin. Med. 129: 193-199.
24. STAMATOYANNOPOLOS, G., R. VEITH, et al. 1990. Induction of fetal hemoglobin by cell-cycle specific drugs and recombinant erythropoietin. Am. J. Ped. Hematol. Oncol. 12: 21-26.
25. ENGELHARD, D., G. CIVIDALLI, et al. 1975. Splenectomy in homozygous beta thalassemia: A retrospective study of 30 patients. Brit. J. Haematol. 31: 391-403.
26. RACHMILEWITZ, E. A., A. GOLDFARB, et al. 1991. Administration of erythropoietin to patients with beta thalassemia intermedia: A preliminary trial. Blood 78: 1145-1147.
27. OLIVIERI, N. F., M. H. FREEDMAN, et al. 1992. Trial of recombinant erythropoietin to patients with beta-thalassemia intermedia. Blood 80: 3258-3260.
28. RACHMILEWITZ, E. A., M. AKER, et al. 1995. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassemia. Br. J. Haematol. 90: 341-345.
29. NISLI, G., K. KAVAKLI, et al. 1996. Recombinant human erythropoietin trial in thalassemia intermedia. J. Trop. Pediatr. 42: 330-334.
30. VAN WYCK, D. B. 1989. Iron management during recombinant human erythropoietin therapy. Am. J. Kidney Dis. 14: 9-13.
31. NAGEL, R. L., E. VICHINSKKY, et al. 1993. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 81: 9-14.
32. BRUGNARA, C., L. A. CHAMBERS, et al. 1993. Red cell regeneration induced by subcutanous recombinant erythropoietin in iron-replete subjects. Blood 81: 956-964.
33. BRUGNARA, C., G. M. COLELLA, et al. 1994. Effects of subcutaneous human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J. Lab. Clin. Med. 123: 660-667.
34. KOOISTRA, M. P., A. VAN Es, et al. 1991. Iron metabolism in patients with anemia of end stage renal disease. Br. J. Haem. 79: 634-639.
35. SHALEV, O., T. REPKA, et al. 1995. Deferriprone (L-1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle RBC both in vitro and in vivo. Blood 86: 2008-2013.
36. VREUGDENHIL, G., G. J. KONTOGHIORGHES, et al. 1991. Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3hydroxypyrid-4-one. Clin. Exp. Rheumatol. 9: 35-40.
37. OLIVIERI, N. R., G. D. SHER, et al. 1995. Long-term treatment with recombinant human erythropoietin in patients with thalassemia: Reduction in requirement for transfusion and chelation therapy. In Sickle Cell Disease and Thalassemias: New Trends in Therapy. Colloque INSERM: 234-305. John Libbey Euro-text Ltd. Montrouge, France.
38. SAUVAGE, C., P. ROUGER-FESSARD, et al. 1993. Improvement of mouse thalassemia by hydroxyurea. Br. J. Haematol. 84: 492-498.
39. ZENO, Y. T., S. Z. HUANG, et al. 1996. Hydroxyurea therapy in thalassemia intermedia: Improvement in hematological parameters due to enhanced β-globin synthesis. Br. J. Haematol. 90: 557-563.
40. DEFRANCESCHI, L. & P. ROUYEV-FESSARD, et al. 1996. Combination chemotherapy of erythropoietin, hydroxyurea, and clotrimaxzole in a thalassemic mouse: A model for human therapy. Blood 87: 1188-1195.
41. ALTER, B. P. & C. K. WAGNER, et al. 1989. Modulation of mouse hemoglobin expression by hydroxyurea and erythropoietin in vivo. Prog. Clin. Biol. Res. 316B: 317-335.
42. AKER, M. & G. DOVER, et al. 1995. Combination of erythropoietin and hydroxyurea results in improved quality and quantity of RBC in 7 patients with thalassemia intermedia. In Sickle Cell Disease and Thalassemia: New Trends in Therapy. Colloque INSERM. John Libbey Eurotext Ltd. 234: 197-199.
43. LOUKOPOULOS, D., E. VASKARDOU, et al. 1993. Effective stimulation of erythropoiesis in thalassemia intermedia with recombinant Human Erythropoietin and Hydroxyurea [abstract]. Blood 82: 357.
44. PERRINE, S. P. & N. F. OLIVIERY, et al. 1994. Butyrate derivatives: New agents for stimulating fetal globin production in the beta-globin disorders. Am. J. Ped. Hematol. Oncol. 16: 67-71.
45. FIBACH, E. & P. KOLLIA, et al. 1995. Hemin induced acceleration of hemoglobin production in immature cultured erythroid cells: Preferential enhancement of fetal hemoglobin. Blood 85: 2967-2974.